Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The results of this study show that c-Jun N-terminal kinase (JNK) activation was associated with the enhancement of docetaxel-induced cytotoxicity by simvastatin in DU145 human prostate cancer cells. To better understand the basic molecular mechanisms, we investigated simvastatin-regulated targets during simvastatin-induced cell death in DU145 cells using two-dimensional (2D) proteomic analysis. Thus, vimentin, Ras-related protein Rab-1B (RAB1B), cytoplasmic hydroxymethylglutaryl-CoA synthase (cHMGCS), thioredoxin domain-containing protein 5 (TXNDC5), heterogeneous nuclear ribonucleoprotein K (hnRNP K), N-myc downstream-regulated gene 1 (NDRG1), and isopentenyl-diphosphate Delta-isomerase 1 (IDI1) protein spots were identified as simvastatin-regulated targets involved in DU145 cell death signaling pathways. Moreover, the JNK inhibitor SP600125 significantly inhibited the upregulation of NDRG1 and IDI protein levels by combination treatment of docetaxel and simvastatin. These results suggest that NDRG1 and IDI could at least play an important role in DU145 cell death signaling as simvastatinregulated targets associated with JNK activation.
Abstract
The results of this study show that c-Jun N-terminal kinase (JNK) activation was associated with the enhancement of docetaxel-induced cytotoxicity by simvastatin in DU145 human prostate cancer cells. To better understand the basic molecular mechanisms, we investigated simvastatin-regulated targets during simvastatin-induced cell death in DU145 cells using two-dimensional (2D) proteomic analysis. Thus, vimentin, Ras-related protein Rab-1B (RAB1B), cytoplasmic hydroxymethylglutaryl-CoA synthase (cHMGCS), thioredoxin domain-containing protein 5 (TXNDC5), heterogeneous nuclear ribonucleoprotein K (hnRNP K), N-myc downstream-regulated gene 1 (NDRG1), and isopentenyl-diphosphate Delta-isomerase 1 (IDI1) protein spots were identified as simvastatin-regulated targets involved in DU145 cell death signaling pathways. Moreover, the JNK inhibitor SP600125 significantly inhibited the upregulation of NDRG1 and IDI protein levels by combination treatment of docetaxel and simvastatin. These results suggest that NDRG1 and IDI could at least play an important role in DU145 cell death signaling as simvastatinregulated targets associated with JNK activation.
참고문헌 (32)
- Katsogiannou M, "The hallmarks of castration-resistant prostate cancers", Cancer Treat Rev, 41, pp.588~597 (2015)
- Krycer JR, "Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective", Biochim Biophys Acta, 1835, pp.219~229 (2013)
- Osmak M, "Statins and cancer: Current and future prospects", Cancer Lett, 324, pp.1~12 (2012)
- Altwairgi AK, "Statins are potential anticancerous agents (Review)", Oncol Rep, 33, pp.1019~1039 (2015)
- Gordon JA, "Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts", Prostate Cancer Prostatic Dis, 19, pp.21~27 (2016)
- Yu O, "Use of statins and the risk of death in patients with prostate cancer", J Clin Oncol, 32, pp.5~11 (2014)
- Bogoyevitch MA, "Inhibitors of c-Jun N-terminal kinases: JuNK no more?", Biochim Biophys Acta, 1784, pp.76~93 (2008)
- Koyuturk M, "Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase", Neurosci Lett, 370, pp.212~217 (2004)
- Chen YJ, "Simvastatin induces NFB", p65 down-regulation and JNK1, ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells, pp.Biochem Pharmacol, 2014[DOI]
- Koyuturk M, "Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK", Cancer Lett, 250, pp.220~228 (2007)
- Gopalan A, "Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK", CHOP, Cancer Lett, pp.2013, 329[DOI]
- Zhang S, "Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways", Anticancer Res, 31, pp.3259~3265 (2011)
- Goc A, "Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis", BMC Cancer, 12, pp.e409~ (2012)
- Chen X, "Mechanistic study of inhibitory effects of atorvastatin and docetaxel in combination on prostate cancer", Cancer Genomics Proteomics, 13, pp.151~160 (2016)
- Pienaar IS, "Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration", J Neural Transm, 116, pp.791~806 (2009)
- Campos-Martorell M, "Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model", J Neurochem, 130, pp.301~312 (2014)
- Ponce J, "The effect of simvastatin on the proteome of detergent-resistant membrane domains: Decreases of specific proteins previously related to cytoskeleton regulation, calcium homeostasis and cell fate", Proteomics, 10, pp.1954~1965 (2010)
- Hwang R, "Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone", J Biol Chem, 279, pp.21239~21247 (2004)
- Cho YE, "Integrative analysis of proteomic and transcriptomic data for identification of pathways related to simvastatin-induced hepatotoxicity", Proteomics, 13, pp.1257~1275 (2013)
- Hirai T, "Protein kinase C (PKC): activation mechanisms and cellular functions", J Biochem, 133, pp.1~7 (2003)
- Huang WC, "Beyond NF- B activation: nuclear functions", J Biomed Sci, 20, pp.e3~ (2013)
- Liu JJ, "Sequencing systemic therapies in metastatic castration-resistant prostate cancer", Cancer Control, 20, pp.181~187 (2013)
- Xie F, "Simvastatin blocks TGF- 1-induced epithelial-mesenchymal transition in human prostate cancer cells", Oncol Lett, 11, pp.3377~3383 (2016)
- Jiang HL, "Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-", SMAD signaling, 2015, pp.6, 16352~16365
- Vincent EE, "Overexpression of the TXNDC5 protein in non-small cell lung carcinoma", Anticancer Res, 31, pp.1577~1582 (2011)
- Wang L, "The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway", Oncogene, 34, pp.4735~4745 (2015)
- Dixon KM, "Dp44mT targets the AKT, TGF- and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells", Br J Cancer, 108, pp.409~419 (2013)
- Barboro P, "Prostate cancer: Prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression", Int J Oncol, 44, pp.1589~1598 (2014)
- Barboro P, "Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in antiandrogen- treated LNCaP cells", PLoS One, 8, pp.e79212~ (2013)
- Clendening JW, "Dysregulation of the mevalonate pathway promotes transformation", Proc Natl Acad Sci U S A, 107, pp.15051~15056 (2010)
- Berthelot K, "Isopentenyl diphosphate isomerase: A checkpoint to isoprenoid biosynthesis", Biochimie, 94, pp.1621~1634 (2012)
- Sharon C, "Inhibition of insulin-like growth factor receptor", AKT, Oncotarget, pp.2015, 6[DOI]